KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$30.7 million.

  • Biomarin Pharmaceutical's Net Income towards Common Stockholders fell 12898.19% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 6147.43%. This contributed to the annual value of $426.9 million for FY2024, which is 15462.08% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Net Income towards Common Stockholders of -$30.7 million as of Q3 2025, which was down 12898.19% from $240.5 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Net Income towards Common Stockholders ranged from a high of $240.5 million in Q2 2025 and a low of -$57.9 million during Q4 2021
  • Its 5-year average for Net Income towards Common Stockholders is $56.2 million, with a median of $40.4 million in 2023.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Net Income towards Common Stockholders crashed by 44001.64% in 2021 and then surged by 828273.09% in 2023.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Net Income towards Common Stockholders stood at -$57.9 million in 2021, then surged by 99.57% to -$249000.0 in 2022, then skyrocketed by 8282.73% to $20.4 million in 2023, then surged by 513.22% to $124.9 million in 2024, then plummeted by 124.61% to -$30.7 million in 2025.
  • Its last three reported values are -$30.7 million in Q3 2025, $240.5 million for Q2 2025, and $185.7 million during Q1 2025.